Literature DB >> 9374173

Comparison of five agents in protecting the cochlea against the ototoxic effects of cisplatin in the hamster.

J A Kaltenbach1, M W Church, B W Blakley, D L McCaslin, D L Burgio.   

Abstract

The purpose of this investigation was to study the ameliorating effects of four agents on cisplatin-induced ototoxicity. Hamsters were given a series of five cisplatin injections either alone or in combination with sodium thiosulfate (STS), diethyldihydrothiocarbamate (DDTC), and S-2(3-aminopropylamino) ethylphosphorothioic acid (WR-2721), or fosfomycin. Ototoxicity was assessed anatomically by quantifying the extent of cochlear damage with the scanning electron microscope and physiologically with measures of the auditory brain stem response. When administered alone, cisplatin induced widespread loss of outer hair cells (OHCs) along much of the cochlea in the hamster, especially in the basal and middle turns, with an average survival of only 56% of the OHC population. In contrast, inner hair cells resisted cisplatin ototoxicity in the hamster. Thus the ameliorative effects of the different test agents were assessed by counting the number of surviving OHCs in each treatment group and comparing with cisplatin-treated controls. STS provided the most effective protection against the ototoxic effects of cisplatin, yielding 91% survival of OHCs. DDTC also reduced the ototoxic effects of cisplatin, yielding 68% survival of OHCs. Cotreatment with WR-2721 and fosfomycin yielded 45% and 52% OHC survival, respectively, and thus did not provide any chemoprotection. The results closely paralleled those based on auditory brain stem response recordings in that the magnitude of threshold shift was proportional to the amount of OHC loss; also, the amount of threshold shift at each frequency was in good agreement with the pattern of hair cell loss along the cochlear spiral. Thus both histologic and physiologic results suggest that STS and DDTC hold promise for ameliorating the ototoxic effects of cisplatin chemotherapy.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9374173     DOI: 10.1016/S0194-59989770020-2

Source DB:  PubMed          Journal:  Otolaryngol Head Neck Surg        ISSN: 0194-5998            Impact factor:   5.591


  9 in total

1.  Is intratympanic injection of erdosteine protective against cisplatin-induced ototoxicity?

Authors:  Issam Saliba; Fouad El Fata
Journal:  Neurotox Res       Date:  2011-10-12       Impact factor: 3.911

Review 2.  Platinum-induced ototoxicity in children: a consensus review on mechanisms, predisposition, and protection, including a new International Society of Pediatric Oncology Boston ototoxicity scale.

Authors:  Penelope R Brock; Kristin R Knight; David R Freyer; Kathleen C M Campbell; Peter S Steyger; Brian W Blakley; Shahrad R Rassekh; Kay W Chang; Brian J Fligor; Kaukab Rajput; Michael Sullivan; Edward A Neuwelt
Journal:  J Clin Oncol       Date:  2012-04-30       Impact factor: 44.544

3.  Amifostine protects against cisplatin-induced ototoxicity in children with average-risk medulloblastoma.

Authors:  Maryam Fouladi; Murali Chintagumpala; David Ashley; Stewart Kellie; Sridharan Gururangan; Tim Hassall; Lindsey Gronewold; Clinton F Stewart; Dana Wallace; Alberto Broniscer; Gregory A Hale; Kimberly A Kasow; Thomas E Merchant; Brannon Morris; Matthew Krasin; Larry E Kun; James M Boyett; Amar Gajjar
Journal:  J Clin Oncol       Date:  2008-08-01       Impact factor: 44.544

4.  WR-2721 (Amifostine) ameliorates cisplatin-induced hearing loss but causes neurotoxicity in hamsters: dose-dependent effects.

Authors:  Michael W Church; Brian W Blakley; Don L Burgio; Anil K Gupta
Journal:  J Assoc Res Otolaryngol       Date:  2004-05-20

Review 5.  The sulfhydryl containing compounds WR-2721 and glutathione as radio- and chemoprotective agents. A review, indications for use and prospects.

Authors:  G A Hospers; E A Eisenhauer; E G de Vries
Journal:  Br J Cancer       Date:  1999-05       Impact factor: 7.640

6.  Pharmacokinetics of sodium thiosulfate in Guinea pig perilymph following middle ear application.

Authors:  Ronald J Schroeder; Jason Audlin; Juntao Luo; Brian D Nicholas
Journal:  J Otol       Date:  2018-02-09

Review 7.  Progress in the Development of Preventative Drugs for Cisplatin-Induced Hearing Loss.

Authors:  Robert A Hazlitt; Jaeki Min; Jian Zuo
Journal:  J Med Chem       Date:  2018-02-01       Impact factor: 7.446

8.  Protective effect of N-acetylcysteine against cisplatin ototoxicity in rats: a study with hearing tests and scanning electron microscopy.

Authors:  Mehmet Akif Somdaş; İnayet Güntürk; Esra Balcıoğlu; Deniz Avcı; Cevat Yazıcı; Saim Özdamar
Journal:  Braz J Otorhinolaryngol       Date:  2018-09-14

9.  [Amifostine otoprotection to cisplatin ototoxicity: a guinea pig study using otoacoustic emission distortion products (DPOEA) and scanning electron microscopy].

Authors:  Miguel Angelo Hyppolito; Antonio A de Oliveira; Ricardo Miranda Lessa; Maria Rossato
Journal:  Braz J Otorhinolaryngol       Date:  2005-12-14
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.